In silico Design, and In vitro Expression of a Fusion Protein Encoding Brucella abortus L7/L12 and SOmp2b Antigens

Golshani, Maryam; Ghasemian, Melina; Gheibi, Nematollah; Bouzari, Saeid

In silico Design, and In vitro Expression of a Fusion Protein Encoding Brucella abortus L7/L12 and SOmp2b Antigens

Document Type : Original Article

Authors

¹ Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran

² Department of Biotechemistry, Qazvin University of Medical Sciences, Qazvin, Iran

Abstract

Background: L7/L12 is a protective antigen conserved in main Brucella pathogens and is considered as potential vaccine candidate. Outer membrane protein 2b is an immunogen conserved in all Brucella pathogens. Materials and Methods: The purpose of the current study was to in silico design a L7/L12-SOmp2b fusion protein and in vitro production of the chimera. Two possible fusion forms, L7/L12-SOmp2b and SOmp2b-L7/L12, were subjected to in silico modeling and analysis. Cloning and expression of the fusion protein has been done in the pET28a vector and Escherichia coli Bl21 (DE3), respectively. Results: Analysis and validation of the fusion proteins three-dimensional models showed that both models are in the range of native proteins. However, L7/L12-SOmp2b structure was more valid than the SOmp2b-L7/L12 model and subjected to in vitro production. The major histocompatibility complex II (MHC-II) epitope mapping using Immune Epitope DataBase indicated that the model contained good MHC-II binders. The L7/L12-Omp2b coding sequence was cloned in pET28a vector. The fusion was successfully expressed in E. coli BL21 by induction with isopropyl-β-d-thiogalactopyranoside. The rL7/L12-SOmp2b was purified with Ni-NTA column. The yield of the purified rL7/L12-SOmp2b was estimated by Bradford method to be 240 μg/ml of the culture. Western blot analysis revealed a specific reactivity with purified rL7/L12-SOmp2b produced in E. coli cells and showed the expression in the prokaryotic system. Conclusions: Our data indicates that L7/L12-SOmp2b fusion protein has a potential to induce both B- and T-cell-mediated immune responses and it can be evaluated as a new subunit vaccine candidate against brucellosis.

Keywords

References

1.	Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis 2007;7:775-86. [PUBMED]
2.	He Y. Analyses of Brucella pathogenesis, host immunity, and vaccine targets using systems biology and bioinformatics. Front Cell Infect Microbiol 2012;2:2. [PUBMED]
3.	Seleem MN, Boyle SM, Sriranganathan N. Brucellosis: A re-emerging zoonosis. Vet Microbiol 2010;140:392-8. [PUBMED]
4.	Oliveira SC, Macedo GC, Almeida LA, Oliveira FS, Oñate A, Cassataro J, et al. Recent advances in understanding immunity against brucellosis: Application for vaccine development. Open Vet Sci J 2010;4:102-8.
5.	Corbel MJ. Brucellosis in Humans and Animals. Geneva, Switzerland: WHO Press, World Health Organization; 2006.
6.	Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun 2005;73:8079-88. [PUBMED]
7.	Perkins SD, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans. FEMS Microbiol Rev 2010;34:379-94. [PUBMED]
8.	He Y, Xiang Z. Bioinformatics analysis of Brucella vaccines and vaccine targets using VIOLIN. Immunome Res 2010;6 Suppl 1:S5. [PUBMED]
9.	Xavier MN, Paixão1 TA, Hartigh AB, Tsolis RM, Santos RL. Pathogenesis of Brucella spp. Open Vet Sci J 2010;4:109-18.
10.	Jain S, Kumar S, Dohre S, Afley P, Sengupta N, Alam SI. Identification of a protective protein from stationary-phase exoproteome of Brucella abortus. Pathog Dis 2014;70:75-83. [PUBMED]
11.	Yang Y, Yin J, Guo D, Lang X, Wang X. Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against Brucella melitensis infection. FEMS Immunol Med Microbiol 2011;61:159-67. [PUBMED]
12.	Skendros P, Boura P. Immunity to brucellosis. Rev Sci Tech 2013;32:137-47. [PUBMED]
13.	Vitry MA, De Trez C, Goriely S, Dumoutier L, Akira S, Ryffel B, et al. Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice. Infect Immun 2012;80:4271-80. [PUBMED]
14.	Yang Y, Wang L, Yin J, Wang X, Cheng S, Lang X, et al. Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine. Mol Immunol 2011;49:175-84. [PUBMED]
15.	Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, et al. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infect Immun 2006;74:2734-41. [PUBMED]
16.	Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. Indian J Med Microbiol 2007;25:188-202. [PUBMED] [Full text]
17.	Bachrach G, Banai M, Fishman Y, Bercovier H. Delayed-type hypersensitivity activity of the Brucella L7/L12 ribosomal protein depends on posttranslational modification. Infect Immun 1997;65:267-71. [PUBMED]
18.	Kazak E, Oliveira SC, Goral G, Akalin H, Yilmaz E, Heper Y, et al.Brucella abortus L7/L12 recombinant protein induces strong Th1 response in acute brucellosis patients. Iran J Immunol 2010;7:132-41. [PUBMED]
19.	Golshani M, Rafati S, Dashti A, Gholami E, Siadat SD, Oloomi M, et al. Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice. Mol Immunol 2015;65:287-92. [PUBMED]
20.	Bachrach G, Banai M, Bardenstein S, Hoida G, Genizi A, Bercovier H. Brucella ribosomal protein L7/L12 is a major component in the antigenicity of brucellin INRA for delayed-type hypersensitivity in Brucella-sensitized guinea pigs. Infect Immun 1994;62:5361-6. [PUBMED]
21.	Golshani M, Vaeznia N, Sahmani M, Bouzari S. In silico analysis of Brucella abortus Omp2b and in vitro expression of SOmp2b. Clin Exp Vaccine Res 2016;5:75-82. [PUBMED]
22.	Golshani M, Rafati S, Nejati-Moheimani M, Pourabdi S, Arsang A, Bouzari S. Protein/Protein, DNA/DNA and DNA/Protein based vaccination strategies using truncated Omp2b against Brucella infection in BALB/c Mice. Int J Med Microbiol 2017. pii: S1438-422130020-6.
23.	Golshani M, Rafati S, Nejati-Moheimani M, Ghasemian M, Bouzari S. Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice. Vet Microbiol 2016;197:47-52. [PUBMED]
24.	Luo DY, Li P, Xing L, Zhao GY, Shi W, Zhang SL, et al. DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chin Med J (Engl) 2006;119:331-4. [PUBMED]
25.	Díaz AG, Clausse M, Paolicchi FA, Fiorentino MA, Ghersi G, Zylberman V, et al. Immune response and serum bactericidal activity against Brucella ovis elicited using a short immunization schedule with the polymeric antigen BLSOmp31 in rams. Vet Immunol Immunopathol 2013;154:36-41.
26.	Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008;9:40. [PUBMED]
27.	Wiederstein M, Sippl MJ. ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 2007;35:W407-10. [PUBMED]
28.	Lovell SC, Davis IW, Arendall WB 3^rd, de Bakker PI, Word JM, Prisant MG, et al. Structure validation by Calpha geometry: Phi, psi and Cbeta deviation. Proteins 2003;50:437-50. [PUBMED]
29.	Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The Proteomics Protocols Handbook. Totowa, NJ: Humana Press Inc.; 2005. p. 571-607.
30.	Sen TZ, Jernigan RL, Garnier J, Kloczkowski A. GOR V server for protein secondary structure prediction. Bioinformatics 2005;21:2787-8. [PUBMED]
31.	Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010;11:568. [PUBMED]
32.	El-Manzalawy Y, Dobbs D, Honavar V. Predicting linear B-cell epitopes using string kernels. J Mol Recognit 2008;21:243-55. [PUBMED]
33.	Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: A new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 2008;9:514. [PUBMED]
34.	Saha S, Raghava GP. AlgPred: Prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res 2006;34:W202-9. [PUBMED]
35.	Golshani M, Rafati S, Jahanian-Najafabadi A, Nejati-Moheimani M, Siadat SD, Shahcheraghi F, et al.In silico design, cloning and high level expression of L7/L12-TOmp31 fusion protein of Brucella antigens. Res Pharm Sci 2015;10:436-45. [PUBMED]
36.	Zhao Z, Li M, Luo D, Xing L, Wu S, Duan Y, et al. Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing a L7/L12 and BLS fusion antigen of Brucella. Vaccine 2009;27:5214-9. [PUBMED]
37.	Yang X, Skyberg JA, Cao L, Clapp B, Thornburg T, Pascual DW. Progress in Brucella vaccine development. Front Biol (Beijing) 2013;8:60-77. [PUBMED]
38.	Avila-Calderón ED, Lopez-Merino A, Sriranganathan N, Boyle SM, Contreras-Rodríguez A. A history of the development of Brucella vaccines. Biomed Res Int 2013;2013:743509.
39.	Zarrini G, Zargham S, Tabatabaei Yazdi M, Behzadiyan Nejad Q, Muhammad Hassan Z. Cloning and overexpression of rplL gene of Brucella abortus in Escherichia coli. Pak J Biol Sci 2006;9:1128-31.
40.	Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 1996;14:959-62. [PUBMED]
41.	Kurar E, Splitter GA. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine 1997;15:1851-7. [PUBMED]
42.	Titball RW. Vaccines against intracellular bacterial pathogens. Drug Discov Today 2008;13:596-600. [PUBMED]
43.	Novagen user protocol TB055 Rev. C 0611JN, pET system manual 11^th Edition. 2011 EMD Chemicals Inc., an affiliate of Merck KGaA, Darmstadt, Germany.p: 4.

Advanced Biomedical Research